Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Holding CARA?
Track your performance easily
CARA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $1.92
Previous Close$0.29
Volume190.90K
Average Volume (3M)764.04K
Market Cap
$16.78M
Enterprise Value-$33.44M
Total Cash (Recent Filing)$56.62M
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 04, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding54,846,639
10 Day Avg. Volume499,662
30 Day Avg. Volume764,037
Standard Deviation0.21
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.50
Enterprise Value/Gross Profit-2.26
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cara Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCARA plans to announce data from the Part A dose-finding portion of the Ph2/3 KOURAGE-1 trial in Notalgia Paresthetica.
Market OpportunityNP is a neuropathic itch indication with no FDA-approved drugs.
Market SizeThe estimated US prevalence of NP is approximately 650,000 patients.
Bears Say
Clinical TrialsCara's last clinical shot on goal for oral difelikefalin failed to demonstrate meaningful clinical benefit vs. placebo.
Financial PerformanceWith $70mn in cash, Cara no longer has sufficient resources for further exploration and is winding down the Ph.2/3 clinical program.
Strategic AlternativesThe company is discontinuing its program in NP and will be exploring strategic alternatives.
---
Ownership Overview
15.90% Insiders
16.00% Mutual Funds
15.92% Other Institutional Investors
52.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CARA FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $0.24 and its highest was $1.92 in the past 12 months.
What is Cara Therapeutics’s market cap?
Currently, no data Available
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on Aug 05, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.274 by $0.004.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Overvalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate is -$0.24.
How many shares outstanding does Cara Therapeutics have?
Cara Therapeutics has 54,846,638 shares outstanding.
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.274. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 402K.
---
Cara Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.78%
12-Months-Change
Fundamentals
Return on Equity
-184.32%
Trailing 12-Months
Asset Growth
-46.06%
Trailing 12-Months
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
CARA Earnings Call
Q4 2024
0:00 / 0:00
---
CARA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aurinia Pharmaceuticals
―
Corcept Therapeutics
―
Kiniksa Pharmaceuticals
―
EyePoint Pharmaceuticals
―
---